Compare ETR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETR | UTHR |
|---|---|---|
| Founded | 1949 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | ETR | UTHR |
|---|---|---|
| Price | $92.15 | $493.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $100.44 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.8M | 411.6K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 4.07 | ★ 26.38 |
| Revenue | ★ $12,730,047,000.00 | $3,128,400,000.00 |
| Revenue This Year | $9.16 | $13.64 |
| Revenue Next Year | $7.39 | $5.78 |
| P/E Ratio | $22.70 | ★ $18.73 |
| Revenue Growth | 7.32 | ★ 13.50 |
| 52 Week Low | $73.15 | $266.98 |
| 52 Week High | $98.58 | $496.73 |
| Indicator | ETR | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 65.89 |
| Support Level | $92.21 | $474.59 |
| Resistance Level | $93.86 | $489.99 |
| Average True Range (ATR) | 1.63 | 10.16 |
| MACD | -0.26 | -0.69 |
| Stochastic Oscillator | 6.88 | 91.64 |
Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.